Venlafaxine versus other anti-depressive agents for depression.

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of venlafaxine in comparison with other anti-depressive agents in alleviating the acute symptoms of major depressive disorder.To review acceptability of treatment with venlafaxine in comparison with other anti-depressive agents.To investigate the adverse effects of venlafaxine in comparison with other anti-depressive agents.

[1]  Rachel Churchill,et al.  Sertraline versus other antidepressive agents for depression. , 2009, The Cochrane database of systematic reviews.

[2]  M. Hotopf,et al.  Are all antidepressants really the same? The case of fluoxetine: a systematic review. , 2006, The Journal of clinical psychiatry.

[3]  Andrea Cipriani,et al.  Imputing missing standard deviations in meta-analyses can provide accurate results. , 2006, Journal of clinical epidemiology.

[4]  A. Nierenberg,et al.  Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. , 2005, The American journal of psychiatry.

[5]  K. Lohr,et al.  Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder , 2005, Annals of Internal Medicine.

[6]  B. D'avanzo,et al.  Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. , 2005, The Journal of clinical psychiatry.

[7]  T. Furukawa,et al.  Imputing response rates from means and standard deviations in meta-analyses , 2005, International clinical psychopharmacology.

[8]  T. Carmody,et al.  An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. , 2004, Controlled clinical trials.

[9]  M. Posternak,et al.  Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. , 2004, Journal of psychiatric research.

[10]  C. Barbui,et al.  Are we going to increase the use of antidepressants up to that of benzodiazepines? , 2004, European Journal of Clinical Pharmacology.

[11]  P. Fortin,et al.  Prevalence and Outcomes of Pharmaceutical Industry—Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[12]  P. Ellis,et al.  Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression , 2004 .

[13]  P. Jewesson,et al.  Industry Sponsorship and Authorship of Clinical Trials Over 20 Years , 2004, The Annals of pharmacotherapy.

[14]  M. Hotopf,et al.  "Wish Bias" in Antidepressant Drug Trials? , 2004, Journal of clinical psychopharmacology.

[15]  Emil H Schemitsch,et al.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[16]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[17]  Christian Gluud,et al.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? , 2003, JAMA.

[18]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[19]  M. Hotopf,et al.  Amitriptyline versus other types of pharmacotherapy for depression. , 2003, The Cochrane database of systematic reviews.

[20]  E. Giller,et al.  Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval Reports , 2003, Neuropsychopharmacology.

[21]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[22]  T. Furukawa,et al.  Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review , 2002, BMJ : British Medical Journal.

[23]  N. Freemantle,et al.  Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. , 2002, The British journal of psychiatry : the journal of mental science.

[24]  Gordon H Guyatt,et al.  Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. , 2002, International journal of epidemiology.

[25]  John Cornell,et al.  A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2 , 2000, Annals of Internal Medicine.

[26]  J. Deakin,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines , 2000 .

[27]  N. Freemantle,et al.  SSRIs versus other antidepressants for depressive disorder. , 2000, The Cochrane database of systematic reviews.

[28]  N. Freemantle,et al.  Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. , 2000, The Cochrane database of systematic reviews.

[29]  S. Montgomery,et al.  Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability , 1997, International clinical psychopharmacology.

[30]  G H Guyatt,et al.  A Consumer's Guide to Subgroup Analyses , 1992, Annals of Internal Medicine.

[31]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[32]  L. Luborsky.  Clinician's judgments of mental health. , 1962, Archives of general psychiatry.

[33]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.